We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00333502
Recruitment Status : Completed
First Posted : June 5, 2006
Last Update Posted : May 28, 2020
Sponsor:
Information provided by (Responsible Party):
Lumos Pharma ( NewLink Genetics Corporation )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects.

OBJECTIVES:

• Determine the safety, toxicity, and the maximum tolerated dose (MTD) of CRLX101 when administered intravenously to subjects with advanced solid tumors.


Condition or disease Intervention/treatment Phase
Cancer Solid Tumor Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
Study Start Date : May 2006
Actual Primary Completion Date : November 2011
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CRLX101 (formerly known as IT-101)
CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
 Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
Other Names:
  • NLG207
  • IT-101


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To determine the safety, toxicity and maximum tolerated dose of CRLX101 when administered intravenously to subjects with advanced solid tumors. [ Time Frame: 6 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects >18 years of age with advanced, histologically-confirmed solid tumors refractory to standard therapy or for which no standard therapy exists and who have evidence of disease progression documented since their prior therapy.
  • Subjects must have measurable or evaluable disease.
  • Subjects must not have received prior chemotherapy or radiation for >/= 4 weeks prior to first dose of study drug.
  • Subjects may be entered if they have received prior radiation therapy involving </= 30% of the bone marrow. Any prior radiation therapy must have been administered >/= 4 weeks prior to first dose of study drug and the subject must be recovered from the acute toxic effects of the treatment prior to study entry.
  • Subjects may be enrolled with a history of treated brain metastases that are clinically stable for >/= 4 weeks prior to first dose of study drug. Subjects may not be currently receiving dexamethasone.
  • ECOG performance status of < 2.
  • Life expectancy of greater than 12 weeks.
  • Subjects must have acceptable organ and marrow function at screening and pre-dose visits.
  • Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator and an acceptable QTc interval.
  • The effects of CRLX101 on the developing human fetus are unknown, therefore, women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Female subjects who are pregnant or nursing.
  • Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study drug or those who have not had adverse events return to baseline severity level or a severity level Grade 1 due to agents administered more than 4 weeks prior to first dose of study drug.
  • Subjects with a history of congestive heart failure (CHF) requiring medical therapy.
  • Subjects with serum amylase or lipase > 1.5X upper limit of normal (ULN).
  • Subjects with previous high dose chemotherapy with autologous stem cell rescue bone marrow transplantation.
  • Use of any investigational agent or drug within 4 weeks prior to first dose of study drug.
  • Metastatic disease to the CNS requiring treatment or radiation therapy.
  • Subjects with known untreated brain metastases or treated brain metastases that have not been stable >/= 4 weeks prior to first dose of study drug.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
  • The presence of active coagulation disorder.
  • Subjects with marked baseline prolongation of QT/QTc interval (QTc interval >/= 470 msec for females and QTc interval >/= 450 msec for males).
  • Any prior treatment with a topoisomerase I inhibitor.
  • Any major surgery </= 4 weeks prior to first dose of study drug.
  • Concurrent use of G-CSF or growth factors at the time of initiation of study drug.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00333502


Locations
Layout table for location information
United States, Arizona
Virginia G. Piper Cancer Center
Scottsdale, Arizona, United States, 85258
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
United States, New Mexico
San Juan Oncology Associates
Farmington, New Mexico, United States, 87401
Sponsors and Collaborators
NewLink Genetics Corporation
Investigators
Layout table for investigator information
Principal Investigator: Yun Yen, M.D., Ph.D. City of Hope National Medical Center
Principal Investigator: Glenn Weiss, M.D. Virginia G. Piper Cancer Center
Principal Investigator: Jeffrey D. Neidhart, M.D. San Juan Oncology Associates
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: NewLink Genetics Corporation
ClinicalTrials.gov Identifier: NCT00333502    
Other Study ID Numbers: CRLX-001
City of Hope IRB number 05127
First Posted: June 5, 2006    Key Record Dates
Last Update Posted: May 28, 2020
Last Verified: May 2020
Keywords provided by Lumos Pharma ( NewLink Genetics Corporation ):
Cancer, Neoplasms, Solid Tumor, Ovarian Cancer, Lung Cancer,
Non Small Cell Lung Cancer, Pancreatic Cancer,
Breast Cancer, Colon Cancer, Endometrial Cancer,
 Kidney (Renal Cell) Cancer, Melanoma, Prostate Cancer,
Skin Cancer, Thyroid Cancer,
Solid Malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Camptothecin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
 Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action